Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026
Rhea-AI Summary
Smith+Nephew (NYSE:SNN) will showcase a comprehensive rotator cuff repair portfolio at AAOS 2026 in New Orleans, featuring the newly acquired Tendon Seam Repair System and the REGENETEN Bioinductive Implant.
Highlights: Tendon Seam has 510(k) clearance (2023); REGENETEN has >250,000 procedures since 2014; AAOS issued a Strong Recommendation for bioinductive implants to lower re-tear rates.
Positive
- AAOS Strong Recommendation for bioinductive implants to lower re-tear rates
- REGENETEN: >250,000 procedures globally since 2014
- Tendon Seam 510(k) clearance in 2023 provides regulatory market access
Negative
- Rotator cuff failure rates remain high at 20–40% with traditional techniques
- US market concentrated: ~500,000 procedures annually, implying competitive pressure
News Market Reaction – SNN
In the Mar 2 session, SNN declined 3.09%, reflecting a moderate negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Distribution agreement | Positive | -0.6% | Exclusive US distribution deal adds A’TOMIC Nitinol fixation to trauma portfolio. |
| Feb 23 | Distribution agreement | Positive | -0.6% | SI-BONE iFuse TORQ agreement expands pelvic fixation and sacroiliac fusion offerings. |
| Jan 21 | Acquisition | Positive | +1.9% | Acquisition of Integrity Orthopaedics brings Tendon Seam RCR system into portfolio. |
| Oct 27 | Clinical outcomes data | Positive | +0.3% | Large real-world study shows PICO sNPWT outperforms Prevena in outcomes and costs. |
| Oct 22 | Partnership extension | Positive | +1.8% | Multi-year UFC marketing extension highlights sports medicine technologies including REGENETEN. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent product and partnership news has generally seen modest, mixed price reactions, with both small gains and small declines following positive strategic updates.
Over the past six months, Smith+Nephew has focused on expanding its sports medicine and orthopaedics portfolio. The Jan 21 2026 acquisition of Integrity Orthopaedics added the Tendon Seam™ RCR system, positioned with REGENETEN for combined biomechanical and biological repair. Subsequent Feb 23–24 2026 distribution deals broadened trauma and fixation offerings but saw slight share pullbacks. Earlier, positive wound-therapy data and a UFC partnership in Oct 2025 supported the sports medicine brand. Today’s AAOS announcement continues this shoulder-repair strategy by showcasing Tendon Seam with REGENETEN.
Key Terms
rotator cuff repair medical
biomechanical repair medical
biological augmentation medical
bioinductive implant medical
510(k) clearance regulatory
Randomized Control Trial (RCT) medical
Clinical Practice Guideline (CPG) medical
soft tissue medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Uniting the most advanced technologies for biomechanical repair and biological augmentation
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase its unrivalled portfolio for rotator cuff repair (RCR) during the 2026 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans this week. RCR is a growing market segment with approximately 500,000 procedures performed annually in the US,1 yet still experiencing 20–
Tendon Seam offers a new and unique biomechanical repair technique alongside market-leading biological augmentation of the REGENETEN Bioinductive Implant, giving Smith+Nephew a differentiated and disruptive RCR portfolio. These technologies aim to drive better outcomes – through immediate biomechanical repair to improve early outcomes and biological augmentation supporting tendon integrity.
The newly acquired Tendon Seam is designed to reduce re‑tear rates and improve patient outcomes versus the current standard of care. Its novel repair stitch configuration with multiple points of fixation, patented microanchors, continuous suture, individually locked stitches, and integrated implantation instrument are designed to deliver strong and stable repairs with a simplified surgical technique. The system received 510(k) clearance in 2023 and is indicated for reattachment of soft tissue to bone, including tendons, ligaments, and joint capsules.
With more than 250,000 procedures4 completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact, offering a better solution for thousands of patients with rotator cuff injuries every year.5 The collagen-based implant supports the body’s natural healing response to facilitate the formation of new tissue to biologically augment repairs – demonstrated by Randomized Control Trial (RCT) data showing improved outcomes versus traditional repair.6-10
This year’s meeting will be the first since AAOS published its revised Clinical Practice Guideline (CPG) that supports the use of bioinductive implants for rotator cuff repair. The American Academy of Orthopaedic Surgeons (AAOS) CPG on the ‘Management of Rotator Cuff Injuries’ highlights the value of bioinductive implants in rotator cuff repair based on independent analysis of studies. Analyzing RCTs for bioinductive implants, AAOS have issued a Strong Recommendation that:
‘The use of bioinductive tendon implants to augment rotator cuff repair, or as an alternative to standard repair, can lead to lower re-tear rates and better patient reported outcomes.’
To learn more about Smith+Nephew’s joint repair solutions for Sports Medicine and our leading rotator cuff repair portfolio, please visit our booth (#839) at AAOS in New Orleans, March 2-6, 2026 or visit www.smith-nephew.com.
- ends –
Media Enquiries
Dave Snyder +1 (978) 749-1440
Smith+Nephew david.snyder@smith-nephew.com
References
- SmartTRAK, 2025, Shoulder Soft Tissue Fixation, 2025 BioMedGPS — SmartTRAK.
- Hein J, et al. Arthroscopy. 2015;31(11):2274-2281.
- Data on File at Integrity Orthopaedics.
- Smith+Nephew. Internal Data.
- FDA. 510(k) Premarket Notification: K242631 [Accessed May 2025]
- Bokor DJ, Sonnabend D, Deady L, et al. Evidence of healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up. Muscles,Ligaments Tendons J 2016;6(1):16-25.
- Bokor DJ, Sonnabend DH, Deady L, et al. Healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a highly porous collagen implant: a 5-year clinical and MRI follow-up. Muscles, Ligaments Tendons J 2019;9(3):338-347.
- Ruiz Iban MA, et al. Arthroscopy. Apr 08 2025 [ePub Ahead of Print].
- Ruiz Iban MA, et al. Arthroscopy. 2024;40(6):P1760-1773.American Academy of Orthopedic Surgeons (AAOS). Rotator Cuff Repair Clinical Practice Guideline. Available at: https://www.aaos.org/quality/quality-programs/rotator-cuff/. [Accessed August 2025].
- Camacho Chacón JA, Roda Rojo V, Martin Martinez A, et al. An isolated bioinductive repair vs sutured repair for full-thickness rotator cuff tears: 2-year results of a double blinded, randomized controlled trial. J Shoulder Elbow Surg. 2024;33(9):1894-1904. doi: 10.1016/j.jse.2024.03.043
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
